Moderna (MRNA) Other Accumulated Expenses (2017 - 2026)

Moderna (MRNA) has 10 years of Other Accumulated Expenses data on file, last reported at $220.0 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $220.0 million, down 12.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $220.0 million (down 12.7% YoY), and the FY2025 annual result was $185.0 million, down 16.29% from the prior year.
• Other Accumulated Expenses advanced to $220.0 million in Q1 2026 per MRNA's latest filing, from $185.0 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $553.0 million in Q3 2022 and troughed at $42.0 million in Q2 2024.
• A 5-year average of $218.3 million and a median of $220.0 million in 2026 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses plunged 82.2% in 2024, then jumped 357.14% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $249.0 million in 2022, then sank by 48.19% to $129.0 million in 2023, then jumped by 71.32% to $221.0 million in 2024, then retreated by 16.29% to $185.0 million in 2025, then gained by 18.92% to $220.0 million in 2026.
• Business Quant data shows MRNA's Other Accumulated Expenses at $220.0 million in Q1 2026, $185.0 million in Q4 2025, and $73.0 million in Q3 2025.